Health AI Central
Share:
Peer-Reviewed Publication
Open Forum Infect Dis2026;13(6):ofag361.June 1, 2026Journal Article

Timing of Bronchoscopy and Plasma Microbial Cell-Free DNA Sequencing in Immunocompromised Host Pneumonia.

Ahmad Mourad1,2, Daniel S Lupu3, Morgan Richey3, Paul Steven4, Vance G Fowler1,2, Brad Perkins3, Thomas L Holland1,2, Stephen P Bergin2,5
1Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
2Duke Clinical Research Institute, Durham, North Carolina, USA.
3Karius Inc, Redwood City, California, USA.
4North American Science Associates Ltd, Selby, United Kingdom.
5Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
PubMed PMC DOI PDF

Abstract

BACKGROUND: Immunocompromised patients are at high risk of pneumonia, with associated poor outcomes. Rapid microbiologic diagnosis is crucial, yet diagnostic yields vary widely. We evaluated the variability in diagnostic yield of usual care testing and plasma microbial cell-free DNA (mcfDNA) sequencing in the prospective observational Pneumonia in the Immunocompromised-Use of the Karius Test for t…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.